M25433

A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions of ABBV-319 in Adult Participants With Systemic Lupus Erythematosus and Sjogren’s Disease

Condition studied : Systemic lupus erythematosus, Gougerot-Sjögren
Treatment : ABBV-319 antibody drug-conjugated
Inclusion criteria :

Systemic lupus erythematosus :
– Have severe, active disease
– Have not responded to disease-modifying treatment
Gougerot-Sjögren syndrome :
– Have severe, active disease

Exclusion criteria :

– Active or previous lupus-related neurological involvement
– Severe renal involvement
– Overlapping connective tissue disorders (except lupus/Gougerot-Sjögren syndrome)

Sponsor : Abbvie
Principal Investigator : Pr. Christian Jorgensen
: NCT06977724
Investigator
Pr. Christian Jorgensen
Directeur de l’IHU
Rechercher sur le site